Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer

Medicine and Dentistry

• Patient 100%
• Bevacizumab 36%
• Cisplatin 22%
• Pemetrexed 22%
• Cells 13%
• Combination Therapy 13%
• Lung Cancer 13%
• Survival Time 13%
• Toxicity 9%
• Therapeutic Procedure 9%
• Overall Survival 9%
• Age 4%
• Adverse Event 4%
• Diseases 4%
• Survival 4%
• Exon 4%
• Adenocarcinoma 4%
• Anemia 4%
• Non Small Cell Lung Cancer 4%
• Clinical Stage 4%
• Epidermal Growth Factor Receptor 4%
• Neutropenia 4%
• Thrombocytopenia 4%
• Adenosquamous Carcinoma 4%

Nursing and Health Professions

• Bevacizumab 36%
• Cisplatin 22%
• Pemetrexed 22%
• Combination Therapy 13%
• Confidence Interval 13%
• Dose 13%
• Lung Cancer 13%
• Survival Time 13%
• Male 9%
• Overall Survival 9%
• Toxicity 9%
• Chemotherapy 9%
• Female 9%
• Adverse Event 4%
• Diseases 4%
• Non Small Cell Lung Cancer 4%
• Anemia 4%
• Survival 4%
• Neutropenia 4%
• Thrombocytopenia 4%
• Adenocarcinoma 4%
• Adenosquamous Carcinoma 4%
• Cancer Center 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 36%
• Cisplatin 22%
• Pemetrexed 22%
• Survival Time 13%
• Lung Cancer 13%
• Toxicity 9%
• Overall Survival 9%
• Adverse Event 4%
• Diseases 4%
• Survival 4%
• Anemia 4%
• Thrombocytopenia 4%
• Non Small Cell Lung Cancer 4%
• Adenocarcinoma 4%
• Neutropenia 4%
• Adenosquamous Carcinoma 4%